Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHLJoanna Zurko, Reem Karmali, Thomas Ollila et al.|Blood Advances|2022Cited by 50
A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphomaGeoffrey Shouse, Alexey V. Danilov, Andy Kaempf et al.|Blood Advances|2023Cited by 49
Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma: Results of a multicenter phase II trialReid W. Merryman, Yazeed Sawalha, Danielle Wallace et al.|Blood|2025Cited by 0